Arcutis Biotherapeutics, Inc.
ARQT· Nasdaq
ARQTArcutis Biotherapeutics, Inc.
Filed Feb 27, 2024 · 10-K · 58 days after period end · 0001787306-24-000031
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020 |
|---|---|---|---|---|
| Revenue | $13.53M | $2.96M | — | — |
| Net Income | -$66.28M | -$72.02M | -$71.33M | -$34.05M |
| EPS Diluted | — | — | — |
Arcutis Biotherapeutics, Inc. · CIK 1787306 · Engraved from SEC EDGAR
| -$0.79 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2023 · filed Feb 27, 2024 · 58 d after period end
